|
1
|
Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial.
|
J Natl Cancer Inst
|
2008
|
6.13
|
|
2
|
Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial.
|
J Natl Cancer Inst
|
2005
|
3.64
|
|
3
|
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.
|
Lancet Oncol
|
2013
|
3.28
|
|
4
|
Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study.
|
J Clin Oncol
|
2002
|
2.27
|
|
5
|
A randomized trial of goal directed vs. standard fluid therapy in cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.
|
J Gastrointest Surg
|
2015
|
2.04
|
|
6
|
Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial.
|
Lancet Oncol
|
2012
|
2.03
|
|
7
|
Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide.
|
J Clin Oncol
|
2005
|
1.87
|
|
8
|
Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use.
|
J Transl Med
|
2012
|
1.60
|
|
9
|
Gemcitabine-based combinations for inoperable pancreatic cancer: have we made real progress? A meta-analysis of 20 phase 3 trials.
|
Cancer
|
2007
|
1.58
|
|
10
|
Chordoma: clinical characteristics, management and prognosis of a case series of 25 patients.
|
BMC Cancer
|
2010
|
1.52
|
|
11
|
A phase III randomized study on the sequencing of radiotherapy and chemotherapy in the conservative management of early-stage breast cancer.
|
Int J Radiat Oncol Biol Phys
|
2005
|
1.49
|
|
12
|
Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients.
|
Cancer
|
2006
|
1.47
|
|
13
|
Does granulocyte colony-stimulating factor worsen anemia in early breast cancer patients treated with epirubicin and cyclophosphamide?
|
J Clin Oncol
|
2006
|
1.45
|
|
14
|
Prognostic significance of lymphocyte morphology in patients with advanced chronic lymphocytic leukemia treated with first line therapy of fludarabine + prednisone.
|
Haematologica
|
2002
|
1.39
|
|
15
|
Adjuvant chemotherapy for bladder cancer: the chance for meta-analyses comparison.
|
Eur Urol
|
2006
|
1.38
|
|
16
|
Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme.
|
Cancer Immunol Immunother
|
2013
|
1.30
|
|
17
|
Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials.
|
Breast Cancer Res Treat
|
2007
|
1.30
|
|
18
|
Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy).
|
Cancer Immunol Immunother
|
2010
|
1.24
|
|
19
|
Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma.
|
Cancer Immunol Immunother
|
2014
|
1.23
|
|
20
|
A novel clinical prognostic score incorporating the number of resected lymph-nodes to predict recurrence and survival in non-small-cell lung cancer.
|
Lung Cancer
|
2009
|
1.17
|
|
21
|
Can patient selection for bladder preservation be based on response to chemotherapy?
|
Cancer
|
2003
|
1.16
|
|
22
|
Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients.
|
Oncology
|
2005
|
1.15
|
|
23
|
Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer?: meta-analysis of randomized trials.
|
Cancer
|
2009
|
1.13
|
|
24
|
IgD multiple myeloma a descriptive report of 17 cases: survival and response to therapy.
|
J Exp Clin Cancer Res
|
2012
|
1.13
|
|
25
|
Clinical features and outcome of familial chronic lymphocytic leukemia.
|
Haematologica
|
2006
|
1.05
|
|
26
|
Adjuvant chemotherapy in muscle-invasive bladder carcinoma: a pooled analysis from phase III studies.
|
Cancer
|
2006
|
1.04
|
|
27
|
Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype.
|
Lung Cancer
|
2012
|
1.02
|
|
28
|
Weekly docetaxel as second line chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials.
|
Cancer Treat Rev
|
2006
|
1.01
|
|
29
|
Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials.
|
J Exp Clin Cancer Res
|
2010
|
1.00
|
|
30
|
Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta-analysis of randomized trials.
|
Cancer
|
2008
|
0.99
|
|
31
|
Laparoscopic and robotic partial nephrectomy without renal ischaemia for tumours larger than 4 cm: perioperative and functional outcomes.
|
World J Urol
|
2012
|
0.99
|
|
32
|
Survival of hereditary non-polyposis colorectal cancer patients compared with sporadic colorectal cancer patients.
|
J Exp Clin Cancer Res
|
2008
|
0.98
|
|
33
|
Molecular analyses and prognostic relevance of HPV in head and neck tumours.
|
Oncol Rep
|
2007
|
0.98
|
|
34
|
Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systematic review of observational studies.
|
Breast
|
2008
|
0.98
|
|
35
|
Magnitude of benefit of adjuvant chemotherapy for non-small cell lung cancer: meta-analysis of randomized clinical trials.
|
Lung Cancer
|
2008
|
0.97
|
|
36
|
Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials.
|
J Exp Clin Cancer Res
|
2011
|
0.96
|
|
37
|
Differentiating chronic lymphocytic leukemia from monoclonal B-lymphocytosis according to clinical outcome: on behalf of the GIMEMA chronic lymphoproliferative diseases working group.
|
Haematologica
|
2010
|
0.96
|
|
38
|
A gender-based score system predicts the clinical outcome of patients with early B-cell chronic lymphocytic leukemia.
|
Leuk Lymphoma
|
2005
|
0.95
|
|
39
|
Gemcitabine at fixed dose-rate in patients with advanced soft-tissue sarcomas: a mono-institutional phase II study.
|
Cancer Chemother Pharmacol
|
2008
|
0.95
|
|
40
|
Increased serum levels of matrix metalloproteinase-9 predict clinical outcome of patients with early B-cell chronic lymphocytic leukaemia.
|
Eur J Haematol
|
2003
|
0.95
|
|
41
|
Impact of hormonal treatment duration in combination with radiotherapy for locally advanced prostate cancer: meta-analysis of randomized trials.
|
BMC Cancer
|
2010
|
0.94
|
|
42
|
Fixed dose-rate gemcitabine infusion as first-line treatment for advanced-stage carcinoma of the pancreas and biliary tree.
|
Cancer
|
2005
|
0.94
|
|
43
|
Letrozole combined with gonadotropin-releasing hormone analog for metastatic male breast cancer.
|
Breast Cancer Res Treat
|
2013
|
0.94
|
|
44
|
Addition of either lonidamine or granulocyte colony-stimulating factor does not improve survival in early breast cancer patients treated with high-dose epirubicin and cyclophosphamide.
|
J Clin Oncol
|
2003
|
0.93
|
|
45
|
Taxanes with anthracyclines as first-line chemotherapy for metastatic breast carcinoma.
|
Cancer
|
2005
|
0.92
|
|
46
|
Vitamin D insufficiency predicts time to first treatment (TFT) in early chronic lymphocytic leukemia (CLL).
|
Leuk Res
|
2011
|
0.91
|
|
47
|
Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer: meta-analytical estimation and implications for therapeutic strategies.
|
Cancer
|
2011
|
0.91
|
|
48
|
Cell surface overexpression of galectin-3 and the presence of its ligand 90k in the blood plasma as determinants in colon neoplastic lesions.
|
Glycobiology
|
2004
|
0.90
|
|
49
|
Adjuvant treatment for resected renal cell carcinoma: are all strategies equally negative? Potential implications for trial design with targeted agents.
|
Clin Genitourin Cancer
|
2013
|
0.90
|
|
50
|
Uterine papillary serous, clear cell, and poorly differentiated endometrioid carcinomas: a comparative study.
|
Int J Gynecol Cancer
|
2011
|
0.90
|
|
51
|
Phase II study of fixed dose rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma multiforme.
|
Cancer Chemother Pharmacol
|
2009
|
0.89
|
|
52
|
Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in the Italian ARCA cohort.
|
J Antimicrob Chemother
|
2012
|
0.89
|
|
53
|
The utility of a prognostic index for predicting time to first treatment in early chronic lymphocytic leukemia: the GIMEMA experience.
|
Haematologica
|
2009
|
0.88
|
|
54
|
Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study.
|
Breast Cancer Res Treat
|
2014
|
0.88
|
|
55
|
Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy.
|
BMC Cancer
|
2012
|
0.88
|
|
56
|
Taxanes as primary chemotherapy for early breast cancer: meta-analysis of randomized trials.
|
Cancer
|
2008
|
0.87
|
|
57
|
First-line treatment with epirubicin and vinorelbine in metastatic breast cancer.
|
J Clin Oncol
|
2002
|
0.86
|
|
58
|
Baff serum level predicts time to first treatment in early chronic lymphocytic leukemia.
|
Eur J Haematol
|
2010
|
0.86
|
|
59
|
Clinical evaluation of the use of exemestane as further hormonal therapy after nonsteroidal aromatase inhibitors in postmenopausal metastatic breast cancer patients.
|
Cancer Invest
|
2007
|
0.86
|
|
60
|
Supracricoid partial laryngectomies after radiation failure: a multi-institutional series.
|
Head Neck
|
2008
|
0.85
|
|
61
|
Serum insulin-like growth factor is not elevated in patients with early B-cell chronic lymphocytic leukemia but is still a prognostic factor for disease progression.
|
Eur J Haematol
|
2006
|
0.85
|
|
62
|
Metastases to the cerebellum. Results and prognostic factors in a consecutive series of 44 operated patients.
|
J Neurooncol
|
2008
|
0.85
|
|
63
|
A phase II trial of docetaxel and vinorelbine in patients with advanced breast cancer previously treated with anthracyclines.
|
Oncology
|
2008
|
0.85
|
|
64
|
Pegylated liposomal doxorubicin in combination with gemcitabine: a phase II study in anthracycline-naïve and anthracycline pretreated metastatic breast cancer patients.
|
Cancer Chemother Pharmacol
|
2005
|
0.85
|
|
65
|
Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme.
|
J Exp Clin Cancer Res
|
2013
|
0.84
|
|
66
|
Targeting targeted agents: open issues for clinical trial design.
|
J Exp Clin Cancer Res
|
2009
|
0.83
|
|
67
|
Serum level of CD26 predicts time to first treatment in early B-chronic lymphocytic leukemia.
|
Eur J Haematol
|
2009
|
0.83
|
|
68
|
Phase II study of epirubicin, oxaliplatin and docetaxel combination in metastatic gastric or gastroesophageal junction adenocarcinoma.
|
J Exp Clin Cancer Res
|
2009
|
0.83
|
|
69
|
Gemcitabine treatment of experimental C6 glioma: the effects on cell cycle and apoptotic rate.
|
Anticancer Res
|
2006
|
0.83
|
|
70
|
A multicenter prospective phase II randomized trial of epirubicin/vinorelbine versus pegylated liposomal doxorubicin/vinorelbine as first-line treatment in advanced breast cancer. A GOIM study.
|
J Exp Clin Cancer Res
|
2011
|
0.83
|
|
71
|
Prognostic value of HER2 and progesterone receptor expression in endometrial carcinoma with positive peritoneal washing.
|
Anticancer Res
|
2007
|
0.83
|
|
72
|
Prognostic relevance of serum levels and cellular expression of adiponectin in B-cell chronic lymphocytic leukemia.
|
Int J Hematol
|
2008
|
0.82
|
|
73
|
Epirubicin plus docetaxel in metastatic breast cancer: escalating dose does not improve efficacy. A phase II study.
|
Anticancer Res
|
2004
|
0.81
|
|
74
|
External validation on a prospective basis of a nomogram for predicting the time to first treatment in patients with chronic lymphocytic leukemia.
|
Cancer
|
2012
|
0.81
|
|
75
|
A phase II trial of gefitinib in combination with capecitabine and oxaliplatin as first-line chemotherapy in patients with advanced colorectal cancer.
|
Curr Med Res Opin
|
2007
|
0.81
|
|
76
|
Prolonged gemcitabine infusion in advanced non-small cell lung carcinoma: a randomized phase II study of two different schedules in combination with cisplatin.
|
Cancer
|
2003
|
0.81
|
|
77
|
Serum angiogenin is not elevated in patients with early B-cell chronic lymphocytic leukemia but is prognostic factor for disease progression.
|
Eur J Haematol
|
2004
|
0.81
|
|
78
|
Docetaxel, oxaliplatin, and capecitabine combination chemotherapy for metastatic gastric cancer.
|
Gastric Cancer
|
2013
|
0.81
|
|
79
|
Altered expression of FAS system is related to adverse clinical outcome in stage I-II breast cancer patients treated with adjuvant anthracycline-based chemotherapy.
|
Clin Cancer Res
|
2004
|
0.81
|
|
80
|
Time to first tumor progression as outcome predictor of a second trasuzumab-based therapy beyond progression in HER-2 positive metastatic breast cancer.
|
Breast J
|
2009
|
0.80
|
|
81
|
Ten years of experience with weekly chemotherapy in metastatic breast cancer patients: multivariate analysis of prognostic factors.
|
Anticancer Drugs
|
2006
|
0.79
|
|
82
|
FOLFIRI as a second-line therapy in patients with docetaxel-pretreated gastric cancer: a historical cohort.
|
J Exp Clin Cancer Res
|
2013
|
0.79
|
|
83
|
Changes in the incidence, pattern of presentation and clinical outcome of early chronic lymphocytic leukemia patients using the 2008 International Workshop on CLL guidelines.
|
Expert Rev Hematol
|
2014
|
0.79
|
|
84
|
Is recurrent venous thromboembolism after therapy reduced by low-molecular-weight heparin compared with oral anticoagulants?
|
Chest
|
2006
|
0.78
|
|
85
|
Phenotypic changes of p53, HER2, and FAS system in multiple normal tissues surrounding breast cancer.
|
J Cell Physiol
|
2005
|
0.78
|
|
86
|
Gemcitabine-oxaliplatin (GEMOX) as salvage treatment in pretreated epithelial ovarian cancer patients.
|
J Exp Clin Cancer Res
|
2013
|
0.78
|
|
87
|
The utility of two prognostic models for predicting time to first treatment in early chronic lymphocytic leukemia patients: results of a comparative analysis.
|
Leuk Res
|
2013
|
0.78
|
|
88
|
Serum levels of syndecan-1 in B-cell chronic lymphocytic leukemia: correlation with the extent of angiogenesis and disease-progression risk in early disease.
|
Leuk Lymphoma
|
2006
|
0.78
|
|
89
|
Myeloid toxicity in breast cancer patients receiving adjuvant chemotherapy: what is the appropriate use of filgrastim?
|
J Clin Oncol
|
2006
|
0.78
|
|
90
|
Italian external and multicentric validation of the MD Anderson Cancer Center nomogram and prognostic index for chronic lymphocytic leukaemia patients: analysis of 1502 cases.
|
Br J Haematol
|
2014
|
0.77
|
|
91
|
Reduction of serum IGF-I levels in patients affected with Monoclonal Gammopathies of undetermined significance or Multiple Myeloma. Comparison with bFGF, VEGF and K-ras gene mutation.
|
J Exp Clin Cancer Res
|
2009
|
0.77
|
|
92
|
New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma: a pooled analysis of the randomized trials.
|
Cancer
|
2005
|
0.77
|
|
93
|
Fludarabine, ara-C, novantrone and dexamethasone (FAND) in previously treated chronic lymphocytic leukemia patients.
|
Haematologica
|
2002
|
0.77
|
|
94
|
Evaluation of renal function under controlled hypotension in zero ischemia robotic assisted partial nephrectomy.
|
Kidney Blood Press Res
|
2014
|
0.77
|
|
95
|
Bevacizumab plus chemotherapy in metastatic colorectal cancer patients treated in clinical practice.
|
Future Oncol
|
2012
|
0.77
|
|
96
|
An integrated psychological strategy for advanced colorectal cancer patients.
|
Health Qual Life Outcomes
|
2006
|
0.77
|
|
97
|
Phase I-II trial of prolonged gemcitabine infusion plus paclitaxel as a biweekly schedule for advanced breast cancer patients pretreated with anthracyclines.
|
Cancer Chemother Pharmacol
|
2010
|
0.77
|
|
98
|
Sequential docetaxel followed by epirubicin-vinorelbine as first-line chemotherapy in advanced breast cancer.
|
Anticancer Res
|
2005
|
0.76
|
|
99
|
Long-term survival in locally advanced oral cavity cancer: an analysis of patients treated with neoadjuvant cisplatin-based chemotherapy followed by surgery.
|
Head Neck
|
2005
|
0.76
|
|
100
|
A prognostic algorithm including a modified version of MD Anderson Cancer Center (MDACC) score predicts time to first treatment of patients with clinical monoclonal lymphocytosis (cMBL)/Rai stage 0 chronic lymphocytic leukemia (CLL).
|
Int J Hematol
|
2014
|
0.76
|
|
101
|
Early switch with aromatase inhibitors as adjuvant hormonal therapy for postmenopausal breast cancer: pooled-analysis of 8794 patients.
|
Cancer Treat Rev
|
2006
|
0.76
|
|
102
|
Eribulin in heavily pretreated metastatic breast cancer patients and clinical/biological feature correlations: impact on the practice.
|
Future Oncol
|
2015
|
0.76
|
|
103
|
Multicenter phase II trial of first-line docetaxel/gemcitabine in advanced breast cancer pretreated with adjuvant anthracyclines.
|
Anticancer Res
|
2009
|
0.76
|
|
104
|
Low-molecular-weight heparin versus oral anticoagulant therapy for the long-term treatment of symptomatic venous thromboembolism: Is there any difference in cancer-related mortality?
|
J Clin Oncol
|
2005
|
0.76
|
|
105
|
Add-on of aripiprazole improves outcome in clozapine-resistant schizophrenia.
|
Prog Neuropsychopharmacol Biol Psychiatry
|
2011
|
0.76
|
|
106
|
Should subgroup analysis of randomized clinical trials have a direct impact on clinical practice?
|
J Clin Oncol
|
2007
|
0.75
|
|
107
|
Treatment of resected non-small-cell lung cancer.
|
N Engl J Med
|
2005
|
0.75
|
|
108
|
HER2/neu expression and hormonal therapy in early breast cancer: can muddy waters become clear?
|
J Clin Oncol
|
2004
|
0.75
|
|
109
|
Effect of vaginally administered DHA fatty acids on pregnancy outcome in high risk pregnancies for preterm delivery: a double blinded randomised controlled trial.
|
J Prenat Med
|
2013
|
0.75
|
|
110
|
Re: Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis.
|
J Natl Cancer Inst
|
2007
|
0.75
|
|
111
|
Re: Mastectomy and oophorectomy by menstrual cycle phase in women with operable breast cancer.
|
J Natl Cancer Inst
|
2002
|
0.75
|
|
112
|
Major bleedings in the comparisons between low-molecular weight heparin versus oral anticoagulant therapy for venous thromboembolism.
|
Thromb Res
|
2006
|
0.75
|
|
113
|
Procedural Pain in Palliative Care: Is It Breakthrough Pain? A Multicenter National Prospective Study to Assess Prevalence, Intensity, and Treatment of Procedure-related Pain in Patients with Advanced Disease.
|
Clin J Pain
|
2016
|
0.75
|
|
114
|
Aromatase inhibitors in post-menopausal metastatic breast carcinoma.
|
Expert Opin Investig Drugs
|
2007
|
0.75
|
|
115
|
Peritoneal carcinomatosis from ovarian epithelial primary: combined aggressive treatment.
|
In Vivo
|
2009
|
0.75
|
|
116
|
Long-term results of a randomized trial on the sequencing of radiotherapy and chemotherapy in breast cancer.
|
Am J Clin Oncol
|
2011
|
0.75
|
|
117
|
A comparison of two questionnaires on Informed Consent for extended criteria liver donors.
|
Ann Ital Chir
|
2015
|
0.75
|
|
118
|
High-dose chronomodulated infusion of 5-fluorouracil (5-FU) and folinic acid (FA) (FF5-16) in advanced colorectal cancer patients.
|
J Cancer Res Clin Oncol
|
2004
|
0.75
|
|
119
|
Adherence to Oral Administration of Endocrine Treatment in Patients With Breast Cancer: A Qualitative Study.
|
Cancer Nurs
|
2016
|
0.75
|
|
120
|
Association between anemia and multiple sclerosis.
|
Eur Neurol
|
2015
|
0.75
|
|
121
|
Self-monitoring versus standard monitoring of oral anticoagulation.
|
Thromb Res
|
2006
|
0.75
|
|
122
|
Zonisamide in Brain Tumor-Related Epilepsy: An Observational Pilot Study.
|
Clin Neuropharmacol
|
2017
|
0.75
|
|
123
|
Oral ondansetron is highly active as rescue antiemetic treatment for moderately emetogenic chemotherapy: results of a randomized phase II study.
|
Support Care Cancer
|
2008
|
0.75
|